Ondansetron Pch

Ondansetron, the active ingredient in Ondansetron Pch, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Pch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Pch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be used when conventional therapy fails.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools may occur. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headedness. - Injection site pain (if administered parenterally): mild discomfort at the injection site.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation that can lead to serious rhythm disturbances. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare but possible when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Neuroleptic malignant-like syndrome: very rare, characterized by fever and muscle rigidity. - Vision changes: blurred vision or visual disturbances.

Before prescribing Ondansetron, clinicians should assess patient history and comorbidities.

- Cardiac risk assessment: evaluate for prolonged QT interval or electrolyte abnormalities. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Hepatic impairment: adjust dose or monitor liver function tests. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Pediatric use: dose must be individualized based on weight and age. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Ondansetron may interact with several medicines that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Amiodarone: combined use can markedly prolong QT interval. - Certain anti‑arrhythmics (e.g., sotalol, quinidine): increase risk of serious ventricular arrhythmias. - Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, fluconazole): may increase ondansetron plasma levels. - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): modestly raise drug exposure. - Digoxin: potential for altered serum concentrations. - Oral contraceptives: may slightly reduce efficacy of hormonal contraception. - Antacids: can affect absorption if taken simultaneously.